Vera Therapeutics Announces Its ORIGIN 3 Study Of TRUTAKNA In Adults With Primary IgA Nephropathy Achieves Primary Endpoint Of Proteinuria Reduction At 36 Weeks

Benzinga

2026.10.22 14:06 (GMT+0)

Benzinga kaynağında aç